liver cancer

Dietary Influences Of Liver Disease Studied

harminka — Wed, 01 Jul 2009 13:55:50 -0500

Diets high in protein and cholesterol are associated with a higher risk of hospitalization or death due to cirrhosis or liver cancer, while diets high in carbohydrates are associated with a lower risk. These findings are in the July issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Hypothyroidism In Women Associated With Liver Cancer

harminka — Mon, 04 May 2009 14:07:35 -0500

Women with a history of hypothyroidism face a significantly higher risk of developing liver cancer, according to a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver liver cancer (AASLD).

New link in liver cancer discovered

harminka — Mon, 30 Mar 2009 11:31:20 -0500

Liver damage can be triggered by various insults, including hepatitis infection or alcohol-induced cirrhosis.

Long-term L-carnitine supplementation prevents development of liver cancer

harminka — Tue, 24 Mar 2009 13:09:01 -0500

A study will be published on March 21, 2009 in World Journal of Gastroenterology addresses the question. A research group in King Saud University, Kingdom of Saudi Arabia investigated, for the first time, the role of carnitine, a naturally occurring compound that is synthesized mainly in the liver, during the development of hepatocarcinogenesis.

New promising drug for treating viral hepatitis and liver cancer

harminka — Mon, 09 Feb 2009 12:42:26 -0600

The Department of Gene Therapy and Hepatology of the Center for Applied Medical Research (CIMA) of the University of Navarra has identified a molecule as possibly effective for improving the treatment of chronic hepatitis and liver cancer.

Hepatitis C virus increases risk of developing liver cancer

harminka — Tue, 23 Dec 2008 12:12:49 -0600

Hepatitis C virus (HCV) causes hepatitis and increased risk of developing liver cancer. Current treatments are expensive, have severe side effects, and fail in about half the patients treated

Liver transplant recipients have higher cancer risk

harminka — Tue, 04 Nov 2008 13:37:58 -0600

A new Canadian study comparing cancer rates of liver transplant patients to those of the general population has found that transplant recipients face increased risks of developing cancer, especially non-Hodgkin's lymphoma and colorectal cancer. Risks were more pronounced during the first year of follow-up and among younger transplant recipients.

If metastasectomy should be performed before other treatments

harminka — Sat, 01 Nov 2008 04:03:02 -0500

Primary HCC is a major cancer related to HBV viral infection in Asian countries, including Japan. Recently, the primary liver cancers are successfully treated by surgical resection including liver transplantation and non-surgical locoregional therapy.

Effect of Curcuma wenyujin on human HepG2 cancer cell

harminka — Wed, 24 Sep 2008 10:47:44 -0500

Hepatocellular carcinoma (HCC) is the fifth most common cancer with more than 1 million fatalities occurring annually worldwide. Nowadays in China, the essential oil of Curcuma wenyujin (CWO) has been used as injection to cure paediatric disease such as acute upper respiratory infections, viral myocarditis and acute pneumonia.

How to differentiate benign from malignant bile duct strictures?

Armen Hareyan — Tue, 09 Sep 2008 12:11:40 -0500

The main etiology of bile duct strictures closely related to the liver is a malignancy (cancer). However, the differentiation of benign and malignant strictures is notoriously difficult.

Down-staged liver cancer associated with good post-transplant outcomes

harminka — Sat, 06 Sep 2008 03:29:49 -0500

Patients with liver cancer can become viable candidates for transplantation if their tumors respond to treatment, a new study suggests.

Advanced liver cancer patients live longer by taking sorafenib

harminka — Thu, 24 Jul 2008 07:06:55 -0500

Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug.